About Mesoblast
Mesoblast is a publicly listed company based in Melbourne (Australia) founded in 2004. Biotherapeutics derived from proprietary adult stem cell-based technologies. The company has 81 employees. Mesoblast has completed 2 acquisitions, including Angioblast Systems and Provasculon. Its website mesoblast.com draws about 13 thousand monthly visits. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells. Its legal entity is MESOBLAST LIMITED.
Company details
Mesoblast specializes in developing cellular medicines. The company has a clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The Japanese Government has approved TEMCELL HS. Inj., a product based on their proprietary allogeneic mesenchymal lineage adult stem cell technology licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft versus host disease in children and adults in Japan. Their product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with the United States Food and Drug Administration (FDA) discussions for children with steroid-refractory acute graft versus host disease. Two other lead product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development in Phase 3 programs targeting, respectively, advanced chronic heart failure and chronic low back pain due to degenerative disc disease.
- Headquarters Melbourne, Australia
- Employees 81
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website mesoblast.com
- Social LinkedIn X
- Legal Name Mesoblast Limited
- Annual Revenue$122.22 M (USD)568.26as on Jun 30, 2026
- Net Profit-$58.44 M (USD)46.2as on Jun 30, 2026
- EBITDA-$43.39 M (USD)27.31as on Jun 30, 2026
- Latest Funding Round$159.98M (USD), Post-IPO
Jan 2025
- InvestorsHercules Capital
& 5 more
- Employee Count81
- Investments & AcquisitionsAngioblast Systems
& 1 more
Funding Insights of Mesoblast
- Total Rounds 16
- Last Round Post-IPO — $159.98M
- First Round $2.7M
(Jun 2005)
- Investors Count 6
Latest 10 of 16 funding rounds of Mesoblast with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $159.98M | Post-IPO | – | – | – |
| Apr 2023 | Post-IPO | – | – | – | |
| Aug 2022 | $45M | Post-IPO | – | – | |
| Mar 2021 | $110M | Post-IPO | – | – | – |
| May 2020 | $90M | Post-IPO | – | – | – |
| Oct 2019 | $50.4M | Post-IPO | – | – | – |
| Mar 2018 | $75M | Debt – Venture | – | – | |
| Mar 2017 | $40M | Post-IPO | – | – | – |
| May 2016 | $6.2M | Grant | – | – | |
| Apr 2015 | $44.89M | Post-IPO | – | – |
6 investors in total: 6 institutional.
Investors in Mesoblast
Mesoblast has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, M&G and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified asset management firm and private fund focused on debt and equity investments in climate startups, real estate, and multiple sectors | 1931 | mandg.com | London, United Kingdom | |
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Provider of public, living relief, strengthening medicare, jobs, skills and training services | 1901 | australia.gov.au | Canberra, Australia | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
| capitalresearch.com.au | ||||
Therapeutics for central nervous system disorders, pain, and cancer | 1987 | cephalon.com | Frazer, United States |
Investor details for Mesoblast
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mesoblast
44 people are tracked at Mesoblast (21 in leadership, 23 in team); the tracked headcount is 81.
| Name | Role | Group |
|---|---|---|
Dagmar Rosa-Bjorkeson | Chief Operating Officer | Leadership |
Dina Pratt | Head Of Human Resources (global) | Leadership |
Christopher James | VP Clinical Operations | Leadership |
Pa Christopher W. James | Vice President, Clinical Operations | Leadership |
Ulrike Rawiel | Associate Director, Data Management | Leadership |
Justin Horst | Head Of Manufacturing | Leadership |
Suman Abraham | Manufacturing Technology, Senior Director | Leadership |
Fiona See | SVP And Head, Translational Research | Leadership |
Geraldine Storton | Head of Regulatory Affairs & Quality Management | Leadership |
Jack Hayes | Vp, Biometrics | Leadership |
Olga Rutman | Associate Director Biostatistics | Leadership |
Silviu Itescu | CEO | Leadership |
Nick Loizos | Vice President New Technology Development | Leadership |
Eric Rose | Chief Medical Officer | Leadership |
Tao Wang | Director， Quality Validation | Leadership |
Danielle Gut | Associate Director, Quality Systems | Leadership |
Andrew Chaponnel | Interim CFO | Leadership |
Roger D. Brown | Divisional VP, Clinical, Regulatory & Quality | Leadership |
David J. Núñez | Director Clinical Development | Leadership |
Juliana Benito | Senior Research Director | Leadership |
24 more people are available in the full profile.
Complete people profiles for Mesoblast
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Mesoblast
Mesoblast is a publicly listed company on the ASX with ticker symbol MSB in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Dec 2004
- Listed onASX: MSB
- Listed entityMESOBLAST LIMITED
- Exchange sectorHealth technology
- ISINAU000000MSB8
- Share price1.99 AUD (-1.97% on the day) · 2026-10-14
- Market capitalisation2,635,080,963.00 AUD
- EPS (diluted, trailing year)-0.07 AUD
- Volume (last session)2,752,449
Financials of Mesoblast
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | 177.5M AUD | -84.9M AUD | -63.0M AUD |
| 2025 | 26.6M AUD | -157.7M AUD | -86.7M AUD |
| 2024 | 9.0M AUD | -134.2M AUD | -82.7M AUD |
| 2023 | 11.2M AUD | -121.7M AUD | -102.1M AUD |
| 2022 | 14.1M AUD | -126.0M AUD | -105.0M AUD |
Detailed financial statements for Mesoblast
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mesoblast
Mesoblast has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Angioblast Systems and Provasculon.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
New blood vessel growth is stimulated through SDF-1 regenerative solutions. | provasculon.com | Cambridge, United States | 2007 | Jun 2013 | •••• | |
Therapeutic products for cardiovascular diseases are developed and commercialized. | angioblast.com | New York, United States | 2001 | May 2010 | •••• |
Complete acquisition details for Mesoblast
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Mesoblast
6 dated milestones of Mesoblast across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Mesoblast is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.7M.
- Acquisition Acquires Angioblast Systems.
- Acquisition Acquires Provasculon.
- Funding Latest funding round, Post-IPO, of $160.0M.
Web traffic of Mesoblast
The website of Mesoblast (mesoblast.com) receives about 12.9K visits a month and ranks #2,261,028 among all websites worldwide, #3,080 in Biotechnology and Pharmaceuticals.
- Monthly visits12.9K
▲ 26.2% vs previous month
- Unique visitors4.4K
per month
- Global rank#2,261,028
among all websites
- Category rank#3,080
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.7
- Average visit51 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with Mesoblast. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| osiris.com | 100% | View details | |||
| celltexbank.com | 77% | 3.1K | #5,568,175 | View details | |
biotechdispatch.com.au | biotechdispatch.com.au | 67% | #2,093,311 | – | |
bhf.org.uk | bhf.org.uk | 59% | #19,762 | – | |
stemcellpioneers.com | stemcellpioneers.com | 58% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Mesoblast
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mesoblast
Complete news archive for Mesoblast
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mesoblast
Mesoblast was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Mesoblast is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Mesoblast has 81 employees.
Annual revenue of Mesoblast is $122.22M as on Jun 30, 2026.
Mesoblast specializes in developing cellular medicines. The company has a clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. These clinical programs target therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The Japanese Government has approved TEMCELL HS. Inj., a product based on their proprietary allogeneic mesenchymal lineage adult stem cell technology licensed to JCR Pharmaceuticals Co. Ltd for the treatment of graft versus host disease in children and adults in Japan. Their product candidate, MSC-100-IV, has orphan drug designation and is being developed under an accelerated regulatory approval pathway in line with the United States Food and Drug Administration (FDA) discussions for children with steroid-refractory acute graft versus host disease. Two other lead product candidates, MPC-150-IM and MPC-06-ID, are in late-stage development in Phase 3 programs targeting, respectively, advanced chronic heart failure and chronic low back pain due to degenerative disc disease.
Yes, Mesoblast is publicly traded on ASX under the ticker symbol MSB.
Mesoblast has made 2 acquisitions, including Angioblast Systems, and Provasculon.
Mesoblast has 6 investors. Key investors include Hercules Capital, M&G, Celgene, Cephalon, and Government of Australia.
Mesoblast operates through Mesoblast Limited.